VPC
ZVRA icon

Vestal Point Capital’s Zevra Therapeutics ZVRA Stock Holding History

Vestal Point Capital’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-525,000
Closed -$3.64M – 91
2024
Q3 		$3.64M Buy
+525,000
New +$3.56M 0.28% 55

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vestal Point Capital's ZVRA Position: Q4 2024 in Review

Vestal Point Capital sold out of Zevra Therapeutics (ZVRA) in Q4 2024, closing a stake of 525,000 shares — an estimated $3.64M sold.

Vestal Point Capital first reported a position in ZVRA in Q3 2024 and held it in 1 quarter. The position peaked at $3.64M in Q3 2024. 109 funds tracked by Wall St. Rank hold ZVRA as of Q4 2024.

  • Vestal Point Capital reported no remaining Zevra Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Vestal Point Capital sold 525,000 Zevra Therapeutics shares in Q4 2024, an estimated $3.64M.
  • Vestal Point Capital first reported a position in Zevra Therapeutics in Q3 2024 and held it in 1 quarter.
  • Vestal Point Capital's Zevra Therapeutics position peaked at $3.64M in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2024.

Based on Vestal Point Capital's 13F filing for Q4 2024, filed 14 Feb 2025.